Image

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

Recruiting
18 years of age
Both
Phase 1

Powered by AI

Overview

This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This study is for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without ezabenlimab. Another purpose is to see whether BI 1831169 can fight cancer. BI 1831169 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1831169 is given to people for the first time.

This study has 2 parts. In Part 1, participants get BI 1831169 alone for up to 3 months. In Part 2, participants get BI 1831169 in combination with ezabenlimab. Participants who take the combination treatment get BI 1831169 for up to 3 months and ezabenlimab for up to 1 year. BI 1831169 is given as an injection into the tumor, or as an infusion into the vein, or both (injection and infusion). Ezabenlimab is given as an infusion into a vein. Participants get the medicines about every 3 weeks. This is called a treatment cycle.

Participants visit the site study site regularly. The number of study visits vary based on the study phase and treatment response. Some visits include an overnight stay. The doctors regularly check the participants' health and monitor the tumors. The doctors also take note of any health problems that could have been caused by BI 1831169 or ezabenlimab.

Eligibility

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic or relapsed/refractory solid tumor.
  • Has accessible lesion(s), the number of accessible lesions depending on the arm into which the patient will be enrolled; either:
    1. For patients being enrolled into an intratumoral (i.t.) containing arm (Arms A, C, D, F), at least one accessible lesion is required, although two are preferred. The lesion(s) must either be easily accessible, or, if not easily accessible, patient must be willing to undergo repeat procedures (e.g., imaging guided procedures) for both biopsies and injections of BI 1831169.
      • If only one accessible lesion is available, this lesion must have a minimum lesion diameter of ≥10mm for injection of BI 1831169 and be amenable to biopsy.
      • If two accessible lesions are available, one must have a minimum lesion diameter of ≥10mm for injection of BI 1831169 and be amenable to biopsy, and the other must be amenable to biopsy.

or

               2. For patients being enrolled into an intravenous (i.v.) only arm (Arms B and E),
                  at least one accessible lesion which is amenable to biopsy. The lesion must
                  either be easily accessible, or, if not easily accessible, patient must be
                  willing to undergo repeat procedures (e.g., imaging guided procedures) for
                  biopsies.
          -  Has failed conventional treatment or for whom no therapy of proven efficacy exists,
             who is not eligible for established treatment options or for whom the available
             treatment options are not suitable. Patient must have exhausted available treatment
             options known to prolong survival for their disease or have refused established
             treatment options for the malignant disease.
          -  Medically fit and willing to undergo all mandatory trial procedures.
          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
          -  Adequate organ function or bone marrow reserve as demonstrated at screening by the
             following laboratory values:
               -  Absolute neutrophil count ≥ 1.5x10^9/L (≥ 1.5x10^3/μL, ≥ 1500/mm^3); platelet
                  count ≥ 100x10^9/L (≥ 100x10^3/μL, ≥ 100x10^3/mm3), without the use of
                  hematopoietic growth factors within 4 weeks of start of trial medication
               -  Hemoglobin ≥ 90 g/L (≥ 9.0 g/dL, ≥ 5.6 mmol/L);
               -  Creatinine ≤ 1.5 times the upper limit of normal (ULN)
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no
                  demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation
                  is attributable to liver metastases.
               -  Total bilirubin ≤ 1.5 x ULN, except for patients with Gilbert's syndrome: total
                  bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
               -  partial thromboplastin time (PTT) / Activated partial thromboplastin time (aPTT)
                  <1.5 x ULN
          -  All toxicities related to previous anti-cancer therapies (including Immune-related
             Adverse Event (irAEs)) have resolved to ≤ Common Terminology Criteria for Adverse
             Events (CTCAE) grade 1 prior to the start of trial treatment (except for alopecia,
             xerostomia and immunotherapy related endocrinopathies which may be included if
             clinically stable on hormone supplements or antidiabetic drugs as per Investigator
             judgement). Any toxicity exceptions not listed here that should not impact the
             patient's participation per the Investigator's judgement should be discussed and
             agreed with the Sponsor.
          -  Patients ≥ 18 years of age or over the legal age of consent in countries where that is
             greater than 18 years at the time of signature of the Informed Consent Form (ICF).
        Further inclusion criteria apply.
        Exclusion Criteria:
          -  Major surgery (major according to the Investigator's assessment) performed within 4
             weeks prior to start of study treatment.
          -  Radiotherapy within 4 weeks prior to the start of study treatment, except in case of a
             brief course of palliative radiotherapy (e.g., for analgesic purpose or for lytic
             lesions at risk of fracture) which can then be completed within two weeks prior to
             start of study treatment.
        Note: No radiation must have been given to any lesions planned to be injected and/or
        biopsied within 6 months of start of treatment.
          -  Active hepatitis B or C infection e.g., Hepatitis B surface antigen (HBsAg) positive,
             or hepatitis C (HCV) antibody (anti-HCV) positive (except if HCV-Ribonucleic Acid
             (RNA) negative), which in the opinion of the Investigator may interfere with
             participation in the trial.
          -  Patients with history of human immunodeficiency virus (HIV) infection who meet one or
             more of the following criteria;
               -  CD4+ count < 350 cells/μL
               -  Viral load > 400 copies/μL (local lab assessment)
               -  Not receiving antiretroviral therapy
               -  Receiving established antiretroviral therapy for less than four weeks prior to
                  the start of study treatment
               -  History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic
                  infections within 12 months prior to start of study treatment Patients with a
                  history of HIV who do not meet any of the criteria above are eligible to
                  participate but the patient must be under the care of an HIV/Infectious Diseases
                  specialist or an HIV/Infectious Diseases specialist must be consulted prior to
                  inclusion.
          -  Any severe or serious, acute or chronic medical or psychiatric condition or laboratory
             abnormality as per Investigator's judgement that may increase the risk associated with
             study participation or study drug administration, including ongoing or active
             infection requiring systemic antibiotics.
          -  Presence of brain tumors, brain metastases and / or carcinomatous meningitis (as per
             cranial imaging Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT),
             performed at most 6 weeks prior to first treatment).
          -  Active infection requiring systemic therapy (antibacterial, antiviral, antiparasitic
             or antifungal therapy) at the start of treatment in the trial.
          -  History of allergy or hypersensitivity to study agent components. Further or exclusion
             criteria apply.

Study details

Solid Tumors

NCT05155332

Boehringer Ingelheim

14 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.